The burden of progressive fibrotic interstitial lung disease across the UK.
Simpson, Thomas Barratt, Shaney L Beirne, Paul Chaudhuri, Nazia Crawshaw, Anjali Crowley, Louise E Fletcher, Sophie Gibbons, Michael A Hallchurch, Philippa Horgan, Laura
Simpson, Thomas
Barratt, Shaney L
Beirne, Paul
Chaudhuri, Nazia
Crawshaw, Anjali
Crowley, Louise E
Fletcher, Sophie
Gibbons, Michael A
Hallchurch, Philippa
Horgan, Laura
Abstract
Almost 15% of new referrals with non-IPF fibrotic ILD go on to develop a progressive fibrotic phenotype and would benefit from antifibrotic therapy https://bit.ly/3uPhClN
MIDER Authors
Citations
Altmetric:
Date
2021-07-08
Type
Article
Subject
Respiratory medicine
Collections
Citation
Simpson T, Barratt SL, Beirne P, Chaudhuri N, Crawshaw A, Crowley LE, Fletcher S, Gibbons MA, Hallchurch P, Horgan L, Jakaityte I, Lewis T, McLellan T, Myall KJ, Miller R, Smith DJF, Stanel S, Thillai M, Thompson F, Wallis T, Wu Z, Molyneaux PL, West AG. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J. 2021 Jul 8;58(1):2100221. doi: 10.1183/13993003.00221-2021
Journal / Source Title
European Respiratory Journal
DOI
10.1183/13993003.00221-2021
PMID
33678609
Publisher
European Respiratory Society
Publisher’s URL
https://erj.ersjournals.com/